The Patent Finder

FIBROBLAST GROWTH FACTOR-21-Fc FUSION PROTEINS

Novartis AG

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/539,280, filed Sep 26, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,006,400FIBROBLAST GROWTH FACTOR-21-Fc FUSION PROTEINS
In force
 · High confidence
Novartis AGIn force
High confidence
US 9,266,935Methods of Treating Metabolic Disorders with an FGF21 Variant
In force
 · High confidence
Novartis AGIn force
High confidence
US 10,076,554FGF21-FC Fusion Proteins for Treating Metabolic Disorders
In force
 · High confidence
Novartis AGIn force
High confidence
US 11,129,874NUCLEIC ACIDS ENCODING FGF21-Fc FUSION PROTEINS
In force
 · High confidence
Novartis AGIn force
High confidence
US 11,944,664Fibroblast Growth Factor-21-Fc Fusion Proteins
In force
 · High confidence
Novartis AGIn force
High confidence
US 12,527,841Fibroblast Growth FACTOR-21-FC Fusion Proteins
In force
 · High confidence
Novartis AGIn force
High confidence
Application 19/426,572Fibroblast Growth FACTOR-21-FC Fusion Proteins
Pending
Not granted
Novartis AGPendingNot granted
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Novartis AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited